Amicus Therapeutics (Nasdaq: FOLD) announced it has commenced the U.S. registration Phase 3 trial with its investigational drug, Amigal(TM) (migalastat hydrochloride) for the treatment of Fabry disease. The Company has reached agreement with the …
Read the full story »A focus on disease-specific efforts by pharmaceutical and biotech companies
Read in depth analysis by industry experts on investing opportunities and business strategies
Learn about corporate strategies, positioning and investing opportunities
Stay on top of the industry with our industry news bulletin
Diversify to hedge your investment during economic turbulence
A well-crafted case study is a powerful educational and marketing tool. The Pharmacy Benefit Management Institute’s (PBMI) 15th Anniversary Drug Benefit Conference offers industry experts an opportunity to present case studies that showcase solutions to …
| NASDAQ | 2236.20 | ||
| S&P 500 | 1104.18 |
